Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...
The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...
Prof Nicholas Schwab and his colleagues found a biomarker which allows to tell in advance if therapy with glatirameracetate will be efficient in an individual MS patent. Treatment with interferon or ...
Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...
Sanofi’s experimental multiple sclerosis drug got hit with two setbacks on Monday: a regulatory delay in the US as well as a failure in a late-stage clinical trial.
As of 2022, there were 15 oral and injectable MS drugs across seven types of "classes," or groups of medication that work in similar ways. These treatments are all pricey, usually costing $5,000 to ...
Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive disease-modifying drugs, a new study has found. Uncertainty about the impact of these drugs during pregnancy ...
New research led by NYU Langone Medical Center examines what happens when a patient with multiple sclerosis (MS) who is clinically stable stops taking their medication. The international, multi-site ...
Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback